196 related articles for article (PubMed ID: 31798693)
1. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States.
Miller EM; Schwartzberg LS
Ther Adv Med Oncol; 2019; 11():1758835919887044. PubMed ID: 31798693
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
3. A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab.
Yang C; Khwaja R; Tang P; Nixon N; King K; Lupichuk S
Curr Oncol; 2022 Jun; 29(6):4224-4234. PubMed ID: 35735446
[TBL] [Abstract][Full Text] [Related]
4. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
5. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of the trastuzumab biosimilar CT-P6.
Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
[No Abstract] [Full Text] [Related]
7. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
8. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of CT-P6 in HER2 positive breast cancer.
Fu C; Stebbing J; Esteva FJ
Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
[No Abstract] [Full Text] [Related]
10. Biosimilar in Breast Cancer: A Narrative Review.
Barman D; Bandyopadhyay T; Talukdar R
Cureus; 2024 Jan; 16(1):e52828. PubMed ID: 38406112
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
Mengato D; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Esteva FJ; Saeki T; Kim H; Stebbing J
Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
[TBL] [Abstract][Full Text] [Related]
13. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
14. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres.
Hester A; Gaß P; Fasching PA; Krämer AK; Ettl J; Diessner J; Wöckel A; Egger T; Stock K; Redlin J; Andraschko M; Harbeck N; Würstlein R
Geburtshilfe Frauenheilkd; 2020 Sep; 80(9):924-931. PubMed ID: 32905322
[No Abstract] [Full Text] [Related]
16. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
17. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
18. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
Hara F; Tajima K; Tanabe K
Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]